🚀 VC round data is live in beta, check it out!
Sartorius Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sartorius and similar public comparables like Quest Diagnostics, Steris, Labcorp, Halma and more.
Sartorius Overview
About Sartorius
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Founded
1978
HQ
Employees
10.3K
Website
Financials (LTM)
EV
$24B
Sartorius Financials
Sartorius reported last 12-month revenue of $4B and EBITDA of $1B.
In the same LTM period, Sartorius generated $2B in gross profit, $1B in EBITDA, and $371M in net income.
Revenue (LTM)
Sartorius P&L
In the most recent fiscal year, Sartorius reported revenue of $4B and EBITDA of $1B.
Sartorius expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $371M | XXX | $314M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sartorius Stock Performance
Sartorius has current market cap of $22B, and enterprise value of $24B.
Market Cap Evolution
Sartorius' stock price is $222.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24B | $22B | 3.5% | XXX | XXX | XXX | $3.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSartorius Valuation Multiples
Sartorius trades at 6.7x EV/Revenue multiple, and 21.9x EV/EBITDA.
EV / Revenue (LTM)
Sartorius Financial Valuation Multiples
As of April 19, 2026, Sartorius has market cap of $22B and EV of $24B.
Equity research analysts estimate Sartorius' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sartorius has a P/E ratio of 58.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22B | XXX | $22B | XXX | XXX | XXX |
| EV (current) | $24B | XXX | $24B | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | 21.9x | XXX | 22.4x | XXX | XXX | XXX |
| EV/EBIT | 31.2x | XXX | 32.5x | XXX | XXX | XXX |
| EV/Gross Profit | 14.3x | XXX | 15.3x | XXX | XXX | XXX |
| P/E | 58.3x | XXX | 68.9x | XXX | XXX | XXX |
| EV/FCF | 69.3x | XXX | 68.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sartorius Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sartorius Margins & Growth Rates
Sartorius' revenue in the last 12 month grew by 8%.
Sartorius' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Sartorius' rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sartorius' rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sartorius Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sartorius Public Comps
See public comps and valuation multiples for other Medical Devices and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sartorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Quest Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Steris | XXX | XXX | XXX | XXX | XXX | XXX |
| Labcorp | XXX | XXX | XXX | XXX | XXX | XXX |
| Halma | XXX | XXX | XXX | XXX | XXX | XXX |
| Illumina | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sartorius M&A Activity
Sartorius acquired XXX companies to date.
Last acquisition by Sartorius was on XXXXXXXX, XXXXX. Sartorius acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sartorius
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSartorius Investment Activity
Sartorius invested in XXX companies to date.
Sartorius made its latest investment on XXXXXXXX, XXXXX. Sartorius invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sartorius
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sartorius
| When was Sartorius founded? | Sartorius was founded in 1978. |
| Where is Sartorius headquartered? | Sartorius is headquartered in United States. |
| How many employees does Sartorius have? | As of today, Sartorius has over 10K employees. |
| Who is the CEO of Sartorius? | Sartorius' CEO is Rene Faber. |
| Is Sartorius publicly listed? | Yes, Sartorius is a public company listed on Euronext Paris. |
| What is the stock symbol of Sartorius? | Sartorius trades under DIM ticker. |
| When did Sartorius go public? | Sartorius went public in 1994. |
| Who are competitors of Sartorius? | Sartorius main competitors are Quest Diagnostics, Steris, Labcorp, Halma. |
| What is the current market cap of Sartorius? | Sartorius' current market cap is $22B. |
| What is the current revenue of Sartorius? | Sartorius' last 12 months revenue is $4B. |
| What is the current revenue growth of Sartorius? | Sartorius revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Sartorius? | Current revenue multiple of Sartorius is 6.7x. |
| Is Sartorius profitable? | Yes, Sartorius is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sartorius? | Sartorius' last 12 months EBITDA is $1B. |
| What is Sartorius' EBITDA margin? | Sartorius' last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Sartorius? | Current EBITDA multiple of Sartorius is 21.9x. |
| What is the current FCF of Sartorius? | Sartorius' last 12 months FCF is $349M. |
| What is Sartorius' FCF margin? | Sartorius' last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Sartorius? | Current FCF multiple of Sartorius is 69.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.